Tolerability and Pharmacokinetics of M2ES in the Treatment of Advanced Solid Tumor

Inclusion Criteria: * Age between 18 and 65 years;Genders eligible for study: both; * Histologic diagnosis of solid malignancies ; * Performance status of 0 or 1; * Tumor not amenable to standard curative or palliative therapy; * life expectancy beyond 3 months; * Ability to give signed informed consent Exclusion Criteria: * Pregnancy or lactation; * Had a history of brain metastasis or a primary brain tumor; * An active, potentially severe autoimmune disease; * Serum creatinine ≥1.5mg/dl or a calculated creatinine clearance \<60ml/min; WBC count \< 2.0×109/L，hemoglobin \< 90g/L，and platelet count \< 100×109/L; Total bilirubin value \< 2.0 times the upper limit of normal (ULN), ALT level \< 2.0 times ULN, AST \< 2.0 times ULN; * Positive of anti-HIV antibodies; * An active infection; * had received chemotherapy or immunotherapy within the prior 4 weeks before study entry * Participation in a clinical study during the last 28 days * QTc with Bazett's correction unmeasurable or ≥ 480 msec on screening ECG